RxDoctor Payments DataLook up a doctor →

Robert Posnick, MD

Dermatology · Nashua, NHNPI 1497866388

Payments from drug & device makers

$991,486in general payments, 2019–2025

Across 2,363 payments — averaging $419.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$318K
  • AbbVie$149K
  • Sun Pharmaceutical Industries Inc.$93K
  • Incyte Corporation$63K
  • Pfizer$56K
  • E.r. Squibb & Sons, L.L.C.$51K
  • plus $262K from 26 others

What the payments were for

  • Consulting fees$50,5855%
  • Speaking & faculty fees$737,33577%
  • Travel & lodging$93,07410%
  • Food & beverage$69,1627%
  • Education$1,3140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$991,486 in reported general payments places this provider in the 95th percentile of 75 dermatology providers in New Hampshire.

See all dermatology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$260,340
Medicare patients
706
Services billed
6,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast47$252,294
Dupixent PenDupilumab33$122,604
Cosentyx Unoready PenSecukinumab12$109,126
Dupixent SyringeDupilumab13$47,295
OpzeluraRuxolitinib Phosphate20$41,737
Halobetasol Propionate57$3,061
Metronidazole63$2,896
Azelaic Acid12$1,793
CiclopiroxCiclopirox Olamine65$1,690
Tretinoin16$1,480
Betamethasone Dipropionate44$1,345
Clobetasol Propionate17$1,088
Ketoconazole52$952
Doxycycline Monohydrate22$854
Triamcinolone Acetonide86$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$317,702$252,29447 claims
Incyte CorporationOpzelura$62,676$41,73720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 dermatology providers in New Hampshire.

Other dermatology in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →